Literature DB >> 7104513

Aggregation of rat neutrophils by nucleotide triphosphates.

A W Ford-Hutchinson.   

Abstract

1 Adenosine 5'-triphosphate (ATP) and uridine 5'-triphosphate (UTP) at concentrations of 3 x 10(-7)M and greater cause a rapid partially reversible aggregation of rat polymorphonuclear leucocytes. 2 Other nucleotide phosphates are much less active at producing aggregation responses; the agonist potencies being UTP greater than ATP greater than guanosine 5'-triphosphate, cytidine 5'-triphosphate, thymidine 5'-triphosphate; ATP greater than adenosine 5'-diphosphate (ADP) greater than adenosine 5'-monophosphate (AMP); and ADP greater than uridine 5'-diphosphate, thymidine 5'-diphosphate, guanosine 5'-diphosphate, cytidine 5'-diphosphate. Adenosine is inactive. 3 The hydrolysis resistant analogues of ATP, alpha-beta-methylene ATP and beta-gamma-methylene ATP, do not cause neutrophil aggregation suggesting that hydrolysis of ATP and UTP may be required to initiate the aggregation response. 4 It is postulated that ATP and UTP may be important stimulants of neutrophil function and may be involved in the adherence of these cells to the vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104513      PMCID: PMC2071794          DOI: 10.1111/j.1476-5381.1982.tb09229.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Evidence that prostaglandin is responsible for the 'rebound contraction' following stimulation of non-adrenergic, non-cholinergic ('purinergic') inhibitory nerves.

Authors:  G Burnstock; T Cocks; B Paddle; J Staszewska-Barczak
Journal:  Eur J Pharmacol       Date:  1975-04       Impact factor: 4.432

2.  Neutrophil aggregation and swelling induced by chemotactic agents.

Authors:  J T O'Flaherty; D L Kreutzer; P A Ward
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

3.  Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.

Authors:  P R Craddock; D Hammerschmidt; J G White; A P Dalmosso; H S Jacob
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

4.  Purinergic receptors.

Authors:  G Burnstock
Journal:  J Theor Biol       Date:  1976-10-21       Impact factor: 2.691

5.  Stimulation of prostaglandin biosynthesis by adenine nucleotides. Profile of prostaglandin release by perfused organs.

Authors:  P Needleman; M S Minkes; J R Douglas
Journal:  Circ Res       Date:  1974-04       Impact factor: 17.367

6.  Contraction and volume changes of glycerol treated rabbit polymorphonuclear leukocytes induced by ATP and Ca 2 ion.

Authors:  L S Hsu; E L Becker
Journal:  Proc Soc Exp Biol Med       Date:  1974-06

7.  Effect of exogenous cyclic AMP and other adenine nucleotides on neutrophil chemotaxis and motility.

Authors:  I Rivkin; E L Becker
Journal:  Int Arch Allergy Appl Immunol       Date:  1976

8.  Substances which aggregate neutrophils. Mechanism of action.

Authors:  J T O'Flaherty; H J Showell; E L Becker; P A Ward
Journal:  Am J Pathol       Date:  1978-07       Impact factor: 4.307

9.  Effects of adenosine 5'-triphosphate (ATP) and beta-gamma-methylene ATP on the rat urinary bladder.

Authors:  C Brown; G Burnstock; T Cocks
Journal:  Br J Pharmacol       Date:  1979-01       Impact factor: 8.739

10.  Phospholipid metabolism and lysosomal enzyme secretion by leukocytes. Effects of dibutyryl cyclic adenosine 3':5'-monophosphate and ATP.

Authors:  J S Tou; C Maier
Journal:  Biochim Biophys Acta       Date:  1976-12-21
View more
  2 in total

1.  Antihemostatic, antiinflammatory, and immunosuppressive properties of the saliva of a tick, Ixodes dammini.

Authors:  J M Ribeiro; G T Makoul; J Levine; D R Robinson; A Spielman
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

Review 2.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.